Results 141 to 150 of about 53,476 (305)
Experimental Physiology, EarlyView.Abstract Chronic kidney disease–mineral and bone disorder (CKD‐MBD) is a major complication of chronic kidney disease (CKD), characterized by disruptions in mineral metabolism, abnormal bone turnover and vascular calcification, which collectively increase the risk of fractures and cardiovascular disease.
Alief Waitupu +4 more
wiley +1 more source
Evidence-Based Complementary and Alternative Medicine, 2016 Osteoporosis has become one of the most prevalent and costly diseases in the world. It is a metabolic disease characterized by reduction in bone mass due to an imbalance between bone formation and resorption.
Tong Xu +5 more
semanticscholar +1 more source
Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets
MedComm, Volume 7, Issue 2, February 2026.This figure emphasizes current understanding of the regulatory networks, approach of diagnose, available preclinical models and clinical management of bone metastasis. to guide future therapeutic development. A deep understanding of these aspects enables the prevention of bone metastasis and the implementation of effective therapeutic strategies ...
Jingyuan Wen +5 more
wiley +1 more source
Experimental and Therapeutic Medicine, 2017 Chlorogenic acid (CGA) is a primary phenolic component of coffee and (-)-epigallocatechin gallate (EGCG) is a primary flavonoid component of green tea, both of which have been documented to possess beneficial health properties.
Kazuhiko Fujita +10 more
semanticscholar +1 more source
MedComm, Volume 7, Issue 2, February 2026.In this study, we identified a previously unrecognized function of HSD17B7 as an ERα‐binding protein that serves as a coactivator to influence trabecular bone mass in estrogen deficiency. Specifically, deleting HSD17B7 in myeloid cells enhanced the number of osteoclasts and decreased trabecular bone mass post‐OVX, compared with control OVX, mirroring ...
Junyue Zhang +7 more
wiley +1 more source
Osteoprotegerin rich tumor microenvironment: implications in breast cancer
OncoTarget, 2016 Osteoprotegerin (OPG) is a soluble decoy receptor for tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL). It belongs to the tumor necrosis factor receptor superfamily (TNFRSF).
Sudeshna Goswami, N. Sharma-Walia
semanticscholar +1 more source
European Journal of Oral Sciences, Volume 134, Issue 1, February 2026.Abstract This study investigated how chronic metformin administration modulates the cellular profile and inflammatory markers in a zoledronic acid‐based rat model of medication‐related osteonecrosis of the jaw (MRONJ). Male Wistar rats were allocated to different treatments: (i) naïve, (ii) MRONJ (zoledronic acid, 0.2 mg/kg, i.v.
Liviane Maria Alves Rabelo +10 more
wiley +1 more source
Circulating Osteoprotegerin in Chronic Kidney Disease and All-Cause Mortality
International Journal of General Medicine, 2021 Joanna Kamińska,1,* Marek Stopiński,1,* Krzysztof Mucha,2,3 Michał Pac,2 Marek Gołębiowski,4 Monika A Niewczas,5,6 Leszek Pączek,2,3 Bartosz Foroncewicz2 1Department of Internal Diseases and Dialysis Unit, West Hospital of Saint John Paul II, Grodzisk ...
Kamińska J +7 more
doaj
Role of Osteoprotegerin as Novel Marker in Urinary Stone Formers: A Pilot Study [PDF]
, 2021 Sreedhar Dayapule +5 more
openalex +1 more source
Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
Cellular Physiology and Biochemistry, 2016 Background/Aims: Bone marrow adipogenesis is one of the major characteristics of aged bone. Bone marrow mesenchymal stem cells (BMMSCs) prefer to differentiate into adipocytes instead of osteoblasts in the bone marrow cavity in aged hosts.
Lili Zhang +7 more
semanticscholar +1 more source